TrialMultiple sclerosis (Houndmills, Basingstoke, England)2021

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

Edward Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.